Search

for
Search:

Research

5 / 1000+ results

research Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure.

November 2020 in “International journal of pharmaceutical compounding”

A stable and simple finasteride suspension was developed that retains over 94.3% of its concentration for up to 90 days and doesn't significantly increase occupational exposure, but safety measures are still advised.

research EXPLORING THE ROLE OF UMBILICAL CORD AND CORD BLOOD IN REGENERATIVE MEDICINE

January 2026 in “Asian Journal of Pharmaceutical and Clinical Research”

Umbilical cord and cord blood stem cells are promising for treating chronic diseases due to their versatility and ethical acceptability.

Purpose-Limited Pharmaceutical Product Claims Under the Revised European Patent Convention: A Camouflaged Attack on Generic Substitution?

research Purpose-limited pharmaceutical product claims under the revised European Patent Convention: A camouflaged attack on generic substitution?

3 citations , January 2010 in “Ghent University Academic Bibliography (Ghent University)”

The revised European Patent Convention may limit generic drug use, affecting healthcare professionals' treatment choices.

research Toxicity of the pharmaceuticals finasteride and melengestrol acetate to benthic invertebrates

July 2020 in “Environmental Science and Pollution Research”

Finasteride harms invertebrates' survival and burial ability.

research Pharmaceutical evaluation of different shampoo brands in local Saudi market

37 citations , October 2017 in “Saudi pharmaceutical journal”

All evaluated shampoos meet Saudi standards.

View more "pharmaceutical acceptability" in research →

Community Join

5 / 1000+ results

community Breezula Phase III 12-Month Data Released by Cosmo Pharma

in Research/Science 39 upvotes 3 months ago

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

community Pelage Pharmaceutical Raises 120 million to continue PP405 Research. Link inside.

in Research/Science 73 upvotes 9 months ago

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

community Kintor Pharmaceutical’s KX-826 Shows Promising Results in Hair Loss Study

in Research/Science 17 upvotes 1 year ago

Kintor Pharmaceutical's KX-826 shows promising results for hair loss treatment. Users discuss the use of anti-androgens like spironolactone and RU58841, noting concerns about concentration and safety.

community Cosmo Pharmaceutical (Breezula) fiscal results. Top Line Six month results expected early in the second half of this year.

in Treatment 25 upvotes 1 year ago

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

community JW Pharmaceutical shows superiority of 'JW0061' in hair growth over existing treatments in US

in Research/Science 99 upvotes 2 years ago

JW0061 shows superior hair growth results compared to existing treatments, with significant increases in hair follicles. The Wnt/β-catenin pathway is crucial for hair growth, and JW0061 activates this pathway effectively.

View more "pharmaceutical acceptability" in community →

Learn

— no results

Try a deeper search in learn →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →